Vaprisol is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro. Vaprisol raises serum sodium concentration by blocking AVP at the V2 receptor, resulting in free water excretion.1
Vaprisol is contraindicated in patients with hypovolemic hyponatremia. Coadministration of Vaprisol with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir, is contraindicated. In addition, in patients unable to make urine, no benefit can be expected. Solutions containing dextrose are contraindicated in patients with known allergy to corn or corn products.
Vaprisol can reliably increase serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia.1 In clinical studies of patients with hyponatremia, Vaprisol significantly increased the baseline-adjusted serum sodium area under the curve during a 4-day period. Learn more.
Monitor serum sodium, volume and neurologic status. Serious neurologic sequelae, including osmotic demyelination syndrome, can result from over rapid correction of serum sodium. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction should be used.
Vaprisol can raise serum sodium in select hospitalized patients with euvolemic and hypervolemic hyponatremia.1 Learn more.
Pregnancy: Based on animal data, Vaprisol may cause fetal harm.
Nursing Mothers: Discontinue drug or nursing taking into consideration importance of drug to mother.
Pediatric Use: Safety and effectiveness in pediatric patients has not been studied.
Severe renal impairment: Vaprisol is not recommended.
Vaprisol does not require dilution and has a well-defined daily dose (10 mg, 20 mg, or 40 mg).1 Learn more.
The most common adverse reactions (incidence ≥10%) reported in clinical trials were infusion site reactions (including phlebitis), pyrexia, hypokalemia, headache and orthostatic hypotension.
REFERENCE: 1. Vaprisol Prescribing Information. Astellas Pharma US, Inc.